Innovent Biologics Inc. is set to present multiple research findings from its biomedicine pipeline at the upcoming American Diabetes Association's $(ADA.AU)$ 85th Scientific Sessions. Scheduled for June 22, 2025, the presentations will include exploratory mechanism-of-action analyses of mazdutide from investigator-initiated trials and a preclinical study of IBI3030, a novel PCSK9-GGG antibody-peptide conjugate. IBI3030 has shown promise in preclinical models for improving cardiovascular risk markers through its multi-target approach. The preclinical study results indicate significant reductions in LDL-c and Lp(a), improved glucose tolerance, weight reduction, and preserved insulin sensitivity. These findings will be showcased during a poster session at the ADA conference, highlighting Innovent's commitment to advancing next-generation therapies in cardiovascular and metabolic diseases.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.